Acriflavine

CAS: 8048-52-0 F: C14H14ClN3 W: 259.73

Acriflavine is a fluorescent dye for labeling high molecular weight RNA. It is also a topical antiseptic. Storage: prote

Contact QiTai

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity	Acriflavine is a fluorescent dye for labeling high molecular weight RNA. It is also a topical antiseptic. Storage: protect from light.
Invitro	Acriflavine is identified as a potent inhibitor of the MCT4 that can inhibit the binding between Basigin and MCT4. Acriflavine significantly inhibits growth and self-renewal potential of several glioblastoma neurosphere lines[1]. The HIF-1 inhibitor acriflavine decreases survival and growth of CML cells. It targets stem cell potential of CML cells[2].
In Vivo	Acriflavine treatment inhibits intratumoral expression of VEGF and tumor vascularization[1]. In a murine CML model, acriflavine decreases leukemia development and reduces LSC maintenance[2]. Acriflavine retards tumor growth in a murine model of breast cancer. The combination of sunitinib with acriflavine significantly decreases vascular endothelial growth factor and TGF-β expression and reduces tumor vasculature followed by increased intratumor necrosis and apoptosis[3].
Name	Acriflavine
CAS	8048-52-0
Formula	C14H14ClN3
Molar Mass	259.73
Appearance	Solid
Transport	Room temperature in continental US; may vary elsewhere.
Storage	4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Reference	[1]. Voss DM, et al. Disruption of the monocarboxylate transporter-4-basigin interaction inhibits the hypoxic response, proliferation, and tumor progression. Sci Rep. 2017 Jun 27;7(1):4292. [2]. Cheloni G, et al. Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine. Blood. 2017 Jun 2. pii: blood-2016-10-745588. [3]. Yin T, et al. HIF-1 Dimerization Inhibitor Acriflavine Enhances Antitumor Activity of Sunitinib in Breast Cancer Model. Oncol Res. 2014;22(3):139-45.